2019年论文
统计方法研究
57.Sheng E., Li W., and Zhou XH. Estimating causal effects of treatment in RCTs with provider and subject noncompliance. Statistics in Medicine 2019; 38: 735-750
58.Fan Y., He M., Su L., and Zhou XH. A Smoothed Q-Learning Algorithm for Estimating Optimal Dynamic Treatment Regimes. Scandinavian Journal of Statistics 2019; 46: 361-660
59.Yu D., Ding C., He N., Wang R., Zhou XH., Shi L. Robust estimation and confidence interval in meta-regression models. Computational Statistics and Data Analysis 2019; 129: 93-118
60.Deng Y., Zhou XH. Methods to control the empirical type I error rate in average bioequivalence tests for highly variable drugs. Statistical methods in medical research, 2019:2147483647-2147483647.
2018年论文
统计方法研究
61.Wu Y., Li Y., Hou Y., Li K., Zhou XH. Study duration for three-arm non-inferiority survival trials designed for accrual by cohorts. Statistical Methods in Medical Research 2018; 27: 507-520.
62.Wang Z., Zhou XH. Biomarker assessment and combination with differential covariate effects and an unknown gold standard, with an application to Alzhiemer's disease. Annals of Applied Statistics 2018; 12: 1204-1227
63.Liu M., He M., and Zhou XH. Modeling Individualized Coefficient Alpha to Measure Quality of Test Score Data. Statistics in Medicine 2018; 37:3230-3243.
64.Zhu K., Huang Y., and Zhou XH. Tree-based ensemble methods for individualized treatment rules. Biostatistics & Epidemiology 2018; 2: 61-83.
65.Taylor L., Zhou XH., Rise P. A Tutorial in Assessing Disclosure Risk in Microdata. Statistics in Medicine 2018; 37: 3693-3706.
66.Yin Y., Cai Z., and Zhou XH. Using secondary outcome to sharpen bounds for treatment harm rate in characterizing heterogeneity, Biometrical Journal 2018; 60: 879-892
67. Yin Y., Zhou XH., Geng Z., Lu F. Assessing the heterogeneity of treatment effects by identifying the treatment benefits harm rate. Statistica Sinica 2018; 28: 137-156.
68.Li W., Jiang Z., Geng Z., and Zhou XH. Identification of causal effects with latent confounding and classical additive errors in treatment. Biometrical Journal 2018;60: 498-515.
医学领域研究
69.Beste L., Chapko M., Zhou XH., Lee S., Esng X., Maier M.M. Hepatitis C cure is associated with decreased healthcare costs in irrhotics in retrospective Veterans Affairs cohort. Digestive Diseases and Sciences 2018; 63:1454-1462.
2017年论文
统计方法研究
70.Ma Y., Zhou XH. Treatment selection in a randomized clinical trial via covariate-specific treatment effect curves. Stat Methods Med Res 2017; 26: 124-141.
71.Zheng C., Zhou XH. Causal mediation analysis on failure time outcome without sequential ignorability. Lifetime Data Analysis 2017; 23: 533-559.
72.Han K, Zhou XH, Liu B. CSTE Curve for Selection the Optimal Treatment When Outcome Is Binary. SCIENCE SINICA Mathematica 2017; 4: 43-60.
73.Wang L., Richardson T., Zhou XH. Causal analysis in multi-arm trials with truncation by death. Journal of Royal Statistical Society Series B 2017; 79: 719-735
74.Wang L., Zhou XH., and Richardson T. S. Identification and Estimation of Causal Effects with Outcomes Truncated by Death. Biometrika 2017;104: 597–612
75. Zhou XH., Wang X., Duncan A., Hu G., Zheng J. Statistical evaluation of adding multiple risk factors improves Framingham stroke risk score. BMC Medical Research Methodology 2017; 17:58.
76.Li W., Zhou XH. Identifiability and Estimation of Causal Mediation Effects with Missing Data. Statistics in Medicine 2017; 36: 3948-3965.
2016年论文
统计方法研究
77.Sheng E., Witten D., and Zhou XH. Hypothesis testing for differentially correlated features. Biostatistics 2016; 17: 677-691.
78.Jin Y., Su Y., Zhou XH., and Huang S. Heterogeneous multimodal biomarkers analysis for Alzheimer's disease via Bayesian network. EURASIP J Bioinform Syst Biol 2016; 1: 1-12.
79.Wang X., Beste L.A., Maier M.M., and Zhou XH. Double robust estimator of average causal treatment effect for censored medical cost data. Statistics in Medicine 2016; 35: 3101-3116.
80. Wang X., Zhou V., Liu Q., Gao Y., and Zhou XH. Evaluation of the accuracy of diagnostic scales for a syndrome in Chinese medicine in the absence of a gold standard. Chinese Medicine 2016; 11: 35.
81.Ding P., Chen H., Geng Z., and Zhou XH. Semiparametric Inference of Complier Average Causal Effect with Nonignorable Missing Outcomes. ACM Transactions on Intelligent Systems and Technology.
82.Bu Y., Zhou XH. Statistical Evaluation of Drug Efficacy for Bridging Study in Companion Diagnostic Test Trials. Journal of Biopharmaceutical Statistics 2016; 26: 1118-1124
83.Hattori S., Zhou XH. Time-dependent summary receiver operating characteristics for meta-analysis of prognostic studies. Statistics in Medicine 2016;26: 4746-4763.
84.Hattori S.,Zhou XH. Evaluation of predictive capacities of biomarkers based on research synthesis. Statistics in Medicine 2016; 35: 4559-4572
医学领域研究
85.Makarov D.V., Hu E., Walter D., Braithwaite R.S., Sherman S., Gold H.T., Zhou XH., Gross C.P., Zeliadt S.B. Appropriateness of Prostate Cancer Imaging among Veterans in a Delivery System without Incentives for Overutilization. Health Services Research 2016; 51: 1021-1051.
86.Besser L.M., Litvan I., Monsell S.E., Mock C., Weintraub S., Zhou XH., Kukull W. Mild cognitive impairment in Parkinson's disease versus Alzheimer's disease. Parkinsonism Relat Disord 2016; 27: 54-60
87.Besser L., Alosco M., Gomez L., Zhou XH., McKee A., Stern R., Gunstad J., Schneider J., Chui H., Kukull W. Late-Life Vascular Risk Factors and Alzheimer’s Disease Neuropathology in Individuals with Normal Cognition. Journal of Neuropathology and Experimental Neurology 2016: 75(10):955-962
88.Zhang Y., Zhou XH., Meranus D.H., Wang L.B., Kukull W.A. Benzodiazepine use and cognitive decline in older adults with normal cognition. Alzheimer Disease & Associated Disorders 2016; 30: 113-117.
89.Monsell S.E., Dodge H.H., Zhou XH., Bu Y., Mock C., Hawes S.E., Kukull W.A., Weintraub S. Results from the NACC Uniform Data Set neuropsychological battery Crosswalk Study. Alzheimer Disease & Associated Disorders 2016; 30: 134-139.
2015年论文
统计方法研究
90.Chen B., and Zhou XH., Chan G. Pseudoempirical-likelihood-based method using calibration for longitudinal data with dropout. JRSS C 2015; 64: 157-174
91.Jin Z., Zhou XH., and He J. Statistical methods for dealing with publication bias in meta-analysis. Statistics in Medicine 2015; 34:343-360. 文章入选为SCI数据库Web of Science高被引论文）
92.Zheng C., Zhou XH. Causal Mediation Analysis in Multi-level Intervention and Multi- component Mediator Case. Journal of Royal Statistical Society Series B (JRSS B) 2015; 77: 581-615.
93.Ding X., Zhou XH., Wang Q. A partially linear single-index transformation model and its nonparametric estimation. Canadian Journal of Statistics 43; 97-117.
94.Wang X., Wang Q., Zhou XH. Partially varying coefficient single-index additive hazard models. Annals of the Institute of Statistical Mathematics 2015; 67: 817-841.
95.Liu W., Zhang B., Zhang Z., Chen B., Zhou XH. A pseudo-likelihood approach for estimating diagnostic accuracy of multiple binary medical tests. Computational Statistics and Data Analysis, 2015, 84, 85-98.
96.Kim E., Zheng D., Zhou XH. Semiparametric transformation models for multiple continuous biomarkers in ROC analysis. Biom J. 2015; 57:808-33.
97.Wu Y., Zhao L., Hou Y., Li K., Zhou XH. Correcting for non-compliance in randomized non-inferiority trials with active and placebo control using structural models. Stat Med 2015; 34: 950-965.
医学领域研究
98.Ke C., Hou Y., Zhang H., Yang K., Wang J., Guo B., Zhang F., Li H., Zhou XH., Li Y., Li K. Plasma metabolic profiles in women are menopause dependent. PLOS ONE 2015;10(11): e0141743.
